ERBB2 and cancer: In this study, we demonstrated that cancer cell-targeted NIR-PIT utilizing pan-IR700 or tra-IR700 is effective against EGFR and HER2 positive EC cells and showed in vitro and in vivo the additive effect of dual-targeted PIT against EC cells and CAFs.